title: Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.
authors.affiliation: Department of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel chernyn@netvision.net.il.
authors.forename: N I
authors.initials: NI
authors.lastname: Cherny
authors.affiliation: Kings Health Partners Integrated Cancer Centre, King's College London, Institute of Cancer Policy, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Sullivan
authors.affiliation: Division of Public Health, Department of Nursing, Laboratory of Biostatistics, University of Athens, Athens, Greece.
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.affiliation: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Kerst
authors.affiliation: Department of Medical Oncology, Ospedale San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Sobrero
authors.affiliation: Division of Oncology, Medical University Vienna, Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Zielinski
authors.affiliation: Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: E G E
authors.initials: EG
authors.lastname: de Vries
authors.affiliation: Department of Medicine, Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium.
authors.forename: M J
authors.initials: MJ
authors.lastname: Piccart
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*